Cargando…

Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy

SIMPLE SUMMARY: Ovarian cancer is among the most malignant gynecologic cancers, in part because intraperitoneal recurrence occurs with high frequency due to occult metastasis. We have demonstrated a metastasis-inhibitory effect of plasma-activated medium (PAM) in ovarian cancer cells. Here, we inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Kae, Yoshikawa, Nobuhisa, Mizuno, Yuko, Ito, Miwa, Tanaka, Hiromasa, Mizuno, Masaaki, Toyokuni, Shinya, Hori, Masaru, Kikkawa, Fumitaka, Kajiyama, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962102/
https://www.ncbi.nlm.nih.gov/pubmed/33799991
http://dx.doi.org/10.3390/cancers13051141
_version_ 1783665405328359424
author Nakamura, Kae
Yoshikawa, Nobuhisa
Mizuno, Yuko
Ito, Miwa
Tanaka, Hiromasa
Mizuno, Masaaki
Toyokuni, Shinya
Hori, Masaru
Kikkawa, Fumitaka
Kajiyama, Hiroaki
author_facet Nakamura, Kae
Yoshikawa, Nobuhisa
Mizuno, Yuko
Ito, Miwa
Tanaka, Hiromasa
Mizuno, Masaaki
Toyokuni, Shinya
Hori, Masaru
Kikkawa, Fumitaka
Kajiyama, Hiroaki
author_sort Nakamura, Kae
collection PubMed
description SIMPLE SUMMARY: Ovarian cancer is among the most malignant gynecologic cancers, in part because intraperitoneal recurrence occurs with high frequency due to occult metastasis. We have demonstrated a metastasis-inhibitory effect of plasma-activated medium (PAM) in ovarian cancer cells. Here, we investigated whether PAM inhibits intraperitoneal metastasis. We observed that PAM induced macrophages’ infiltration into the disseminated lesion, which was co-localized with inducible nitric oxide synthase (iNOS)-positive signal, indicating that PAM might induce M1-type macrophages. We also observed that intraperitoneal washing with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Intraperitoneal washing therapy might be effective to improve clinical outcomes of ovarian cancer. ABSTRACT: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The major cause of EOC’s lethality is that intraperitoneal recurrence occurs with high frequency due to occult metastasis. We had demonstrated that plasma-activated medium (PAM) exerts a metastasis-inhibitory effect on ovarian cancer in vitro and in vivo. Here we investigated how PAM inhibits intraperitoneal metastasis. We studied PAM’s inhibition of micro-dissemination onto the omentum by performing in vivo imaging in combination with a sequential histological analysis. The results revealed that PAM induced macrophage infiltration into the disseminated lesion. The iNOS-positive signal was co-localized at the macrophages in the existing lesion, indicating that PAM might induce M1-type macrophages. This may be another mechanism of the antitumor effect through a PAM-evoked immune response. Intraperitoneal lavage with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Our results demonstrated the efficiency and practicality of aqueous plasma for clinical applications.
format Online
Article
Text
id pubmed-7962102
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79621022021-03-17 Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy Nakamura, Kae Yoshikawa, Nobuhisa Mizuno, Yuko Ito, Miwa Tanaka, Hiromasa Mizuno, Masaaki Toyokuni, Shinya Hori, Masaru Kikkawa, Fumitaka Kajiyama, Hiroaki Cancers (Basel) Article SIMPLE SUMMARY: Ovarian cancer is among the most malignant gynecologic cancers, in part because intraperitoneal recurrence occurs with high frequency due to occult metastasis. We have demonstrated a metastasis-inhibitory effect of plasma-activated medium (PAM) in ovarian cancer cells. Here, we investigated whether PAM inhibits intraperitoneal metastasis. We observed that PAM induced macrophages’ infiltration into the disseminated lesion, which was co-localized with inducible nitric oxide synthase (iNOS)-positive signal, indicating that PAM might induce M1-type macrophages. We also observed that intraperitoneal washing with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Intraperitoneal washing therapy might be effective to improve clinical outcomes of ovarian cancer. ABSTRACT: Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. The major cause of EOC’s lethality is that intraperitoneal recurrence occurs with high frequency due to occult metastasis. We had demonstrated that plasma-activated medium (PAM) exerts a metastasis-inhibitory effect on ovarian cancer in vitro and in vivo. Here we investigated how PAM inhibits intraperitoneal metastasis. We studied PAM’s inhibition of micro-dissemination onto the omentum by performing in vivo imaging in combination with a sequential histological analysis. The results revealed that PAM induced macrophage infiltration into the disseminated lesion. The iNOS-positive signal was co-localized at the macrophages in the existing lesion, indicating that PAM might induce M1-type macrophages. This may be another mechanism of the antitumor effect through a PAM-evoked immune response. Intraperitoneal lavage with plasma-activated lactate Ringer’s solution (PAL) significantly improved the overall survival rate in an ovarian cancer mouse model. Our results demonstrated the efficiency and practicality of aqueous plasma for clinical applications. MDPI 2021-03-07 /pmc/articles/PMC7962102/ /pubmed/33799991 http://dx.doi.org/10.3390/cancers13051141 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nakamura, Kae
Yoshikawa, Nobuhisa
Mizuno, Yuko
Ito, Miwa
Tanaka, Hiromasa
Mizuno, Masaaki
Toyokuni, Shinya
Hori, Masaru
Kikkawa, Fumitaka
Kajiyama, Hiroaki
Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy
title Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy
title_full Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy
title_fullStr Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy
title_full_unstemmed Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy
title_short Preclinical Verification of the Efficacy and Safety of Aqueous Plasma for Ovarian Cancer Therapy
title_sort preclinical verification of the efficacy and safety of aqueous plasma for ovarian cancer therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7962102/
https://www.ncbi.nlm.nih.gov/pubmed/33799991
http://dx.doi.org/10.3390/cancers13051141
work_keys_str_mv AT nakamurakae preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT yoshikawanobuhisa preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT mizunoyuko preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT itomiwa preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT tanakahiromasa preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT mizunomasaaki preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT toyokunishinya preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT horimasaru preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT kikkawafumitaka preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy
AT kajiyamahiroaki preclinicalverificationoftheefficacyandsafetyofaqueousplasmaforovariancancertherapy